Menu
Not yet recruiting NCT07430566

Trauma Exposure and Suicidal Behaviors in Adolescents Aged 11-17 Hospitalized in Child and Adolescent Psychiatry

No phase Interventional Suicidal Ideation and Behavior Psychiatric Hospitalization

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Blood samples, genetic analysis, Questionnaires and scales.
Who it may be relevant to
Registry conditions: Suicidal Ideation and Behavior, Psychiatric Hospitalization. Basic parameters: 11 years — 17 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

It is a comparative monocentric study with longitudinal follow-up at 6 months in adolescents aged between 11 years and 17 years inclusive admitted to complete hospitalization either for suicidal behaviors or for other psychiatric causes. The objective is to explore the experiences of hospitalized adolescents regarding hospitalization, as well as their perceptions of the factors involved in their remission and their experience of the traumatic event(s) if they have been exposed.

Detailed description

Suicidal behaviors among adolescents are a major public health issue. Traumatic exposure (sexual abuse, violence, serious accidents) is a recognized risk factor for psychopathology and suicidality, but its precise links with suicide recurrence, comorbid psychopathology, and neurodevelopmental vulnerability remain little studied.

Hypotheses:

* Traumatic exposure is more common among suicidal adolescents than non-suicidal. * It is associated with an increased risk of recurrence within 6 months. * The neurodevelopmental load, irritability, PTSD and lack of resilience factors modulate this risk. * Specific inflammatory biological profiles could be associated with suicidality.

Originality and innovative aspects:

* Multidimensional approach: clinical, psychometric, biological and qualitative. * Constitution of a biobank for future analyses (inflammatory, genetic, epigenetic). * Inclusion of a qualitative component exploring the subjective experience of hospitalized adolescents. * Integrated analysis of risk, protective and biological factors to guide personalized prevention.

The main objective is to compare the frequency of traumatic exposure history evaluated with the validated questionnaire in French of the CPC version child, among adolescents aged between 11 years old and 17 years inclusive admitted to hospital, either for suicidal behaviors (suicide group), either for other psychiatric causes without a history of suicidal behavior (non-suicidal group).

Interventions

  • Biological Blood samples
    A blood test will be carried out during the inclusion visit, on site, with collection of the time of completion, the last food samples and tobacco consumption. A 2.5 mL Paxgene® tube for whole blood RNA and a 5 mL dry tube for serum will be collected.
  • Genetic genetic analysis
    If consent for genetic analyses is obtained, a 4.5 mL EDTA tube to collect native DNA will be taken during the blood test
  • Other Questionnaires and scales
    * Child Posttraumatic Checklist (CPC) * Life Event Checklist (LEC-5) * Posttraumatic CheckList-5 * K-SADS * Affective Reactivity Index (ARI) * Child Youth Resilience Measure * Adverse Childhood Experiences International Questionnaire (ACE-IQ) * Metacognitions Questionnaire (MCQ-A) * Cognitive Emotion Regulation Questionnaire (CERQ) * Adolescent Dissociative Experience Scale (A-DES) * Behavioral Rating Inventory of Executive Function Self-Report (BRIEF-2)

Primary outcome measures

  • CPC Questionnaire child version [Time frame: Baseline]
Secondary outcome measures (12)
  • CPC questionnaire parents version [Time frame: Baseline]
  • Questionnaire Life Event Checklist (LEC-5) [Time frame: Baseline]
  • Schedule for Affective Disorders and Schizophrenia for school-age children (KSADS) full-life version [Time frame: Baseline]
  • Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5) [Time frame: Baseline]
  • Affective Reactivity Index (ARI) [Time frame: Baseline]
  • Child Youth Resilience Measure (CYRM) [Time frame: Baseline]
  • Adverse Childhood Experiences International Questionnaire (ACE-IQ) [Time frame: Baseline]
  • CER-Q [Time frame: Baseline]
  • BRIEF-2 [Time frame: Baseline]
  • Meta-Cognitions Questionnaire for Adolescents (MCQ-A) [Time frame: Baseline]
  • DES-A [Time frame: Baseline]
  • Neurodevelopmental score [Time frame: Baseline]

Eligibility criteria

Common Inclusion Criteria:

  • Age between 11 and 17 years inclusive
  • Admitted for full-time psychiatric hospitalization
  • Obtaining consent from at least one of the adolescent's legal representatives and the adolescent's personal assent

Inclusion Criteria - "Suicidal Group":

\- Reason for admission: suicidal behavior (suicide attempt)

Inclusion Criteria - "Non-Suicidal Group":

\- Reason for admission: other psychiatric causes (including suicidal thoughts without suicide attempt and non-suicidal self-injurious behavior)

Common Exclusion Criteria:

\- Neither parent available to participate in the intervention

Exclusion Criterion - "Non-Suicidal Group":

\- History of suicidal behavior prior to the current hospitalization

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07430566 · RECHMPL25_0312 · 2025-A02017-42

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗